Diplomat Pharmacy — Q3 2019 Earnings Presentation
12 slides from Diplomat Pharmacy's earnings presentation, Nov 12, 2019
Slide 1: Third Quarter 2019 Operating Results
Copyright © 2019 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved. Jacque , Diplomat Patient Third Quarter 2019 Operating Results November 12 , 2019 Exhibit 99.2
Slide 2: Disclaimers
Disclaimers 2 NON - GAAP INFORMATION We define Adjusted EBITDA as net income (loss) before interest expense, income taxes, depreciation and amortization, share - based compensation, change in fair value of contingent consideration and other merger and acquisition - related expenses, restructuring an
Slide 3: Opening Remarks
Copyright © 2019 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved. Opening Remarks Brian Griffin, Chairman and CEO
Slide 4: 3Q 2019 Highlights
3Q 2019 Highlights $ 1.3 B ( - 5 %) Revenue $12M ( - 73%) Adjusted EBITDA 1 4 ● Strong growth in infusion therapies ● Payer reimbursement compression ● Volume deterioration in certain therapy classes ● PBM contract losses & pricing concession s ● PBM litigation reserve ● PBM contractual volume rebat
Slide 5: Financial Results
Copyright © 2019 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved. Financial Results Dan Davison, CFO
Slide 6: 3Q 2019 Financial Results Summary
3Q 2019 Financial Results Summary 6 Revenue: $1.4B Adjusted EBITDA 1 : $42M GAAP Net Income : $0.2 M GAAP EPS: $0.00 Revenue: $ 1.3 B Adjusted EBITDA 1 : $ 12 M GAAP Net Loss 2 : ( $ 177 M) GAAP EPS 2 : ($ 2.35 ) 3Q18 3Q19 1. A reconciliation of Adjusted EBITDA, a non - GAAP measure, to net ( loss)
Slide 7: 3Q 2019 Segment Details
3 Q 2019 Segment Details 7 Specialty PBM Revenue: $ 1.2 B Gross margin: 5.2 % Rx volume: 237,000 Net Sales/Rx: $ 5,221 Gross profit/Rx: $ 268 Revenue: $82 M Gross margin 1 : (1.4%) Rx volume*: 922,000 Gross profit 1 /Rx: ($1) * Adjusted to 30 - day equivalent, where a 90 - day prescription is counte
Slide 8: Revised 2019 Full-Year Outlook
Revised 2019 Full - Year Outlook 8 1. A reconciliation of Adjusted EBITDA, a non - GAAP measure, to net ( loss) income, as prepared in accordance with GAAP can be found in the Appendix to this presentation. $4.6B – $4.7B $ 325 M – $ 375 M $4.9B – $5.1B Specialty Revenue PBM Revenue Total Revenue Tot
Slide 9: Appendix: Supplemental Financial Information
Copyright © 2019 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved. Appendix Supplemental Financial Information
Slide 10: Reconciliation of Net Loss to Adjusted EBITDA
10 Reconciliation of Net Loss to Adjusted EBITDA 2019 2018 2019 2018 Net (loss) income (177,280)$ 169$ (351,043)$ (4,244)$ Depreciation 1,684 1,586 5,010 4,702 Amortization 15,375 22,791 53,509 67,845 Interest expense 11,659 10,179 32,044 30,998 Income tax (benefit) expense (2,087) (121) (1,034) 750
Slide 11: Revised 2019 Full-Year Outlook: GAAP to Non-GAAP Reconciliation
Revised 2019 Full - Year Outlook : GAAP to Non - GAAP Reconciliation 11 1. Cash interest is expected to be $38 to $37 million between the low - and high - range respectively. Low High Net (loss) income attributable to Diplomat Pharmacy, Inc. (368,091)$ (360,566)$ Depreciation and amortization 73,500
Slide 12: Supplemental Information: Net Debt
Supplemental Information: Net Debt 1 12 1 Net debt is defined as total debt including contingent consideration less cash and equivalents. As of September 30, 2019As of December 31, 2018 Borrowings on line of credit 105,000$ 176,300$ Term loan A 136,875 142,500 Term loan B 319,000 322,000 Contingent